ProQR Therapeutics (PRQR) Operating Expenses (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Operating Expenses for 15 consecutive years, with $17.8 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses rose 0.8% year-over-year to $17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.6 million (up 16.25% YoY) and the FY2025 annual result came in at $68.0 million, up 19.55% from the prior year.
• Operating Expenses eased to $17.8 million in Q1 2026 per PRQR's latest filing, from $120.4 million in the prior quarter.
• Over the last five years, Operating Expenses for PRQR reached as high as $142.7 million in Q4 2022 and fell as low as -$23.6 million in Q3 2022.
• A 5-year average of $17.9 million and a median of -$11.4 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 805.41% — and 2025, when it slumped 61.26%.
• Year by year, Operating Expenses stood at $142.7 million in 2022, then slumped by 43.94% to $80.0 million in 2023, then grew by 21.66% to $97.3 million in 2024, then advanced by 23.7% to $120.4 million in 2025, then tumbled by 85.17% to $17.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $17.8 million, $120.4 million, and -$16.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.